APA (7th ed.) Citation

S, E., CB, H., KE, S., Y, H., CA, P., C, Y., . . . GD, T. (2025). Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): A first-in-human, open-label, randomised controlled phase 1 trial. The lancet. HIV, 12(1), e13. https://doi.org/10.1016/S2352-3018(24)00247-9

Chicago Style (17th ed.) Citation

S, Edupuganti, et al. "Safety, Tolerability, Pharmacokinetics, and Neutralisation Activities of the Anti-HIV-1 Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination with VRC07-523LS in Adults Without HIV in the USA (HVTN 136/HPTN 092): A First-in-human, Open-label, Randomised Controlled Phase 1 Trial." The Lancet. HIV 12, no. 1 (2025): e13. https://doi.org/10.1016/S2352-3018(24)00247-9.

MLA (9th ed.) Citation

S, Edupuganti, et al. "Safety, Tolerability, Pharmacokinetics, and Neutralisation Activities of the Anti-HIV-1 Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination with VRC07-523LS in Adults Without HIV in the USA (HVTN 136/HPTN 092): A First-in-human, Open-label, Randomised Controlled Phase 1 Trial." The Lancet. HIV, vol. 12, no. 1, 2025, p. e13, https://doi.org/10.1016/S2352-3018(24)00247-9.